10-QPeriod: Q3 FY2008

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2008

Filed November 3, 2008For Securities:ABT

Summary

Abbott Laboratories reported strong financial performance for the third quarter and the first nine months of 2008, driven by significant sales growth across its key segments, particularly Pharmaceuticals and Vascular Products. Net sales increased by 17.6% to $7.5 billion for the quarter and by 15.4% to $21.6 billion for the nine-month period, benefiting from both organic growth and favorable foreign exchange rates. Diluted earnings per share also saw substantial improvement, rising to $0.69 for the quarter and $2.14 for the nine months, reflecting robust operating performance and effective cost management. The company's strategic actions, including the conclusion of the TAP Pharmaceutical Products Inc. joint venture and the acquisition of the Lupron business, are expected to contribute positively to future results. While the company faces ongoing litigation and restructuring charges, management anticipates these will not materially impact its overall financial position. Abbott's liquidity remains strong, supported by healthy operating cash flows and significant available credit facilities, positioning it well to navigate the current economic environment and continue investing in its growth pipeline.

Financial Highlights

31 data points
Beta

Revenue

$7.50B

55.3% Gross Margin

Net Income

$1.08B

14.5% Net Margin

EPS (Diluted)

$0.69

Cash & Equivalents

$2.81B

Free Cash Flow

$2.38B

Financial Statements
Beta
Revenue$7.50B
Cost of Revenue$3.35B
Gross Profit$4.14B
SG&A Expenses$2.07B
Operating Expenses$6.10B
Operating Income$1.40B
Interest Expense$125.01M
Net Income$1.08B
EPS (Basic)$0.70
EPS (Diluted)$0.69
Shares Outstanding (Basic)1.55B
Shares Outstanding (Diluted)1.56B

Key Highlights

  • 1Net sales for the third quarter of 2008 reached $7.5 billion, a 17.6% increase year-over-year, driven by strong performance in Pharmaceuticals and Vascular Products.
  • 2Diluted earnings per share for the third quarter were $0.69, a significant increase from $0.46 in the prior year period.
  • 3The conclusion of the TAP Pharmaceutical Products Inc. joint venture on April 30, 2008, resulted in Abbott acquiring the Lupron business and recognizing a $94 million gain.
  • 4Research and development expenses increased by 6.2% in the quarter, reflecting continued investment in pipeline programs across oncology, immunology, and other key areas.
  • 5Abbott announced a new restructuring plan in Q3 2008 for its diagnostic business, expected to incur pre-tax charges of approximately $370 million over several years.
  • 6The company's liquidity position remains strong, with $5.8 billion in net cash from operating activities for the first nine months of 2008 and $4.0 billion in unused credit lines.
  • 7A new $5 billion share repurchase program was authorized in October 2008, following the completion of a prior $2.5 billion authorization.

Frequently Asked Questions

Abbott Laboratories reported a strong third quarter in 2008, with net sales increasing by 17.6% to $7.5 billion and diluted earnings per share rising to $0.69, up from $0.46 in the same period last year. This growth was broad-based across its key segments.

The conclusion of the TAP joint venture on April 30, 2008, led to Abbott acquiring the Lupron business. This transaction resulted in a $94 million gain and the recording of significant intangible assets and goodwill. Abbott also began recording Lupron sales directly and expects to receive approximately $1.4 billion in future payments from Takeda.

Abbott is involved in various legal proceedings and investigations. While management believes most of these will not have a material adverse effect on the company's financial position, cash flows, or results of operations, certain specific cases, including those related to pricing information and patent disputes, could have a material impact. The company has recorded reserves for estimated losses, with a total estimated range of possible loss between $145 million and $355 million.

Abbott increased its R&D spending by 6.2% in the third quarter, focusing on key pipeline programs. Concurrently, it initiated a new restructuring plan for its diagnostic business, aiming to improve efficiencies, which is expected to incur pre-tax charges of approximately $370 million over several years. These investments and restructuring efforts are part of Abbott's strategy to drive future growth and profitability.